share_log

海正药业(600267.SH):拟以5000万元参与吉盛澳玛增资

Zhejiang Hisun Pharmaceutical (600267.SH): plans to invest 50 million yuan in Jisheng Aoma's capital increase.

Gelonghui Finance ·  Dec 27, 2024 17:13

Gelonghui, December 27th丨Zhejiang Hisun Pharmaceutical (600267.SH) announced that Nanjing Jisheng Aoma Biomedical Co., Ltd. (referred to as "Jisheng Aoma") was established in 2021, with its main product indications including allergic rhinitis, allergic dermatitis, respiratory infections, vaccine adjuvants, etc. To support its own Innovative Drugs research and development, Jisheng Aoma plans to raise no more than 0.1 billion yuan in financing recently. Given that the disease areas of Jisheng Aoma's pipeline products align with the company's Global Strategy, in order to promote cooperation with Jisheng Aoma and advance the company's own Innovative Drugs development, the company agrees to participate in this round of capital increase of Jisheng Aoma with 50 million yuan from its own funds. If Jisheng Aoma's current financing amount is fully subscribed, the company will Hold 10.4167% of Jisheng Aoma's shares.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment